SPOTLIGHT -
Dr. Koo on Degarelix for the Treatment of Prostate Cancer
Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association, discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.
Read More
Dr. Koo Discusses Focal Therapy for Prostate Cancer
Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.
Dr. Koo on Active Surveillance Rates in Prostate Cancer
Alec Koo, MD, FACS, managing partner, Skyline Urology, board of directors, LUGPA, discusses results from a recent study on active surveillance in prostate cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL